Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
Laura J. Hay, a director of MetLife, Inc. (MET) reported a non-derivative acquisition of 26 shares of MetLife common stock executed on 09/09/2025 at a reported price of $79.29 per share. After the transaction she is shown as beneficially owning 3,727 shares directly. The filing states this transaction reflects the imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning shares that became payable were deferred and recorded as additional common stock.
This disclosure is routine for director deferred compensation arrangements and documents a small, internal equity accrual rather than an open-market purchase or sale.
MetLife director William E. Kennard reported an imputed reinvestment of dividends that resulted in the acquisition of 312 shares of MetLife common stock at an implied price of $79.29 per share on 09/09/2025. After this transaction he beneficially owns 43,918 shares, held directly and indirectly, with indirect holdings attributable to shares held in the MetLife Policyholder Trust. The filing notes the acquisition arose from the Deferred Compensation Plan for Non-Management Directors, where payable shares were deferred and reinvested.
MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock. The Form 4 shows an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, resulting in an acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share. Following the transaction, the reporting person beneficially owned 6,838 shares. The filing was signed by an attorney-in-fact on 09/11/2025. The disclosure reflects a routine dividend reinvestment rather than an open-market purchase or exercise of options.
MetLife, Inc. filed an initial ownership report for executive Adrienne Karen O'Neill, who serves as EVP & Chief Accounting Officer. As of the event date of September 2, 2025, the filing states that she has no MetLife securities beneficially owned, shown as zero shares in the non-derivative holdings table and no derivative securities listed.
This Form 3 provides a baseline disclosure of her ownership position as a newly reported officer, confirming that she starts with no reported direct or indirect equity holdings in MetLife common stock or related derivative instruments.
MetLife, Inc. filed an 8-K reporting a news release dated September 2, 2025, that it will redeem all outstanding shares of its 3.850% fixed rate reset non‑cumulative preferred stock, Series G, on September 15, 2025. The filing notes the cover page interactive data is provided in Inline XBRL and is signed by Timothy J. Ring, Senior Vice President and Secretary.
MetLife, Inc. announced dividend declarations for multiple preferred stock series. The company declared a quarterly dividend of $0.35263005 per share on its floating-rate Series A preferred (with a $25 liquidation preference). It also declared a semi-annual dividend of $29.375 per share on Series D (5.875% fixed-to-floating, $1,000 liquidation preference), a quarterly dividend equal to $351.5625 per share on Series E (5.625%, $25,000 liquidation preference; $0.3515625 per depositary share representing 1/1,000th), a quarterly dividend equal to $296.875 per share on Series F (4.75%, $25,000 liquidation preference; $0.296875 per depositary share representing 1/1,000th), and a semi-annual dividend of $19.250 per share on Series G (3.850%, $1,000 liquidation preference). The release is attached as Exhibit 99.1 and incorporated by reference.
MetLife, Inc. filed a Form 13F Combination Report disclosing holdings managed by its investment subsidiaries. The report lists 6 table entries with a total market value of $10,392,142. The filing is signed by John McCallion, EVP, CFO and Head of MetLife Investment Management, dated 08-13-2025.
MetLife, Inc. — Schedule 13D/A (Amendment No. 102)
The Board of Directors, acting as the sole reporting person, updates its disclosure on common stock held in the MetLife Policyholder Trust formed during the 2000 demutualization. As of 31-Jul-2025 the Trust owns 108,242,821 shares, representing 16.28 % of outstanding stock. The Board possesses shared voting power over all shares but no sole voting or dispositive power; economic rights remain with policyholder beneficiaries.
The position declined by 1,161,259 shares since the 28-Apr-2025 amendment, primarily from beneficiary withdrawals, the Trust’s purchase-and-sale program and routine escheatment. No director paid consideration for the shares and no new acquisitions, sales or strategic actions are announced. Voting mechanics, beneficiary withdrawal rights and other trust provisions remain unchanged. Apart from the routine share reduction, the filing contains no material transactions or changes in corporate control intent.